Health Jun 10

FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego
FDA advisers back Alzheimer’s drug that can slow disease

If the agency agrees with the panel's recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. shown to convincingly slow cognitive decline and memory problems due to Alzheimer's.